1316214-52-4 2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]嘧啶-5-甲酰胺

中文名称: 2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]嘧啶-5-甲酰胺
英文名称: 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
CAS号

词条详情加载中…

名称和标识

中文名: 2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]嘧啶-5-甲酰胺
英文名: 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
CAS号: 1316214-52-4
分子式: C24H27N5O3
分子量: 433.5
中文别名: Ricolinostat; 2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]-5-嘧啶羧酰胺; 2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]-5-嘧啶甲酰胺; ACY1215; Rocilinostat
英文别名: Ricolinostat; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; ACY-1215; ACY-63; Rocilinostat; ACY 63; ACY 1215; cc-661; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; 5-Pyrimidinecarboxamide, 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-

物化属性

LogP: 1.41
Num. H-bond acceptors: 5.0
Num. H-bond donors: 3.0
PSA: 114.43000
TPSA: 107.45 Å²

安全信息

安全说明

危险性质：非危险化学品

生产及用途

用途与制备

生命科学，是一种有效、选择性的 HDAC6 抑制剂，信号转导通路激酶抑制剂，药物活性分子。

医药

合成路线 1（1. 合成：1316214-52-4）

产率：48% 合成条件：Stage #1: With sodium hydroxide In methanol; dichloromethane at 0℃; for 0.17 h; Stage #2: With hydroxylamine In methanol; dichloromethane; water at 0 - 20℃; for 0.33 h; Stage #3: With hydrogenchloride In water 实验步骤：将化合物6（2.0g，4.6mmol），氢氧化钠（2N，20mL）在MeOH（50ml）和DCM（25ml）中的混合物在0℃下搅拌10分钟。将羟胺（50％）（10ml）冷却至0℃并加入混合物中。将得到的混合物在室温下搅拌20分钟。除去溶剂后，将混合物用1M HCl中和，得到白色沉淀。将粗产物过滤并通过预HPLC纯化，得到白色固体（950mg，48％）。 参考文献：

[1] Patent: WO2011/91213, 2011, A2. Location in patent: Page/Page column 73; 75-76 [2] Patent: WO2013/13113, 2013, A2. Location in patent: Page/Page column 70 [3] Patent: US2015/99744, 2015, A1. Location in patent: Paragraph 0237 [4] Patent: US2015/105384, 2015, A1. Location in patent: Paragraph 0406 [5] Patent: US2015/105358, 2015, A1. Location in patent: Paragraph 0396-0397 [6] Patent: US2015/119413, 2015, A1. Location in patent: Paragraph 0158-0159 [7] Patent: US2015/105409, 2015, A1. Location in patent: Paragraph 0203 [8] Patent: US2015/105383, 2015, A1. Location in patent: Paragraph 0217 [9] Patent: US2015/150871, 2015, A1. Location in patent: Paragraph 0254-0255 [10] Patent: WO2016/7423, 2016, A1. Location in patent: Page/Page column 39 [11] Patent: WO2016/87950, 2016, A1. Location in patent: Page/Page column 28 [12] Patent: US2016/355486, 2016, A1. Location in patent: Paragraph 0138; 0143 [13] Patent: WO2016/200919, 2016, A1. Location in patent: Page/Page column 20; 21 [14] Patent: US9663825, 2017, B2. Location in patent: Page/Page column 157 [15] Patent: US2017/114023, 2017, A1. Location in patent: Paragraph 0125; 0130 [16] Patent: WO2017/184774, 2017, A1. Location in patent: Page/Page column 44; 45 [17] Patent: WO2017/214565, 2017, A1. Location in patent: Page/Page column 34; 35 [18] Patent: WO2018/81556, 2018, A1. Location in patent: Page/Page column 28; 29 [19] Patent: WO2018/98168, 2018, A1. Location in patent: Page/Page column 31 [20] Patent: WO2018/85652, 2018, A1. Location in patent: Page/Page column 30 [21] Patent: WO2018/81585, 2018, A1. Location in patent: Page/Page column 33 [22] Patent: WO2018/98348, 2018, A1. Location in patent: Page/Page column 28; 29 [23] Patent: WO2017/143237, 2017, A1. Location in patent: Page/Page column 48; 50